A detailed history of Northern Trust Corp transactions in A Tyr Pharma Inc stock. As of the latest transaction made, Northern Trust Corp holds 130,814 shares of LIFE stock, worth $243,314. This represents 0.0% of its overall portfolio holdings.

Number of Shares
130,814
Previous 118,456 10.43%
Holding current value
$243,314
Previous $184,000 32.07%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$1.51 - $2.24 $18,660 - $27,681
12,358 Added 10.43%
130,814 $243,000
Q2 2024

Aug 14, 2024

BUY
$0.0 - $2.07 $0 - $39,930
19,290 Added 19.45%
118,456 $184,000
Q1 2024

May 14, 2024

SELL
$1.42 - $2.02 $1,329 - $1,890
-936 Reduced 0.94%
99,166 $193,000
Q4 2023

Feb 13, 2024

BUY
$1.11 - $1.51 $23,957 - $32,590
21,583 Added 27.49%
100,102 $141,000
Q3 2023

Nov 13, 2023

SELL
$1.55 - $2.23 $57,985 - $83,424
-37,410 Reduced 32.27%
78,519 $124,000
Q2 2023

Aug 11, 2023

BUY
$1.72 - $2.57 $77,957 - $116,482
45,324 Added 64.19%
115,929 $250,000
Q1 2023

May 15, 2023

BUY
$1.88 - $2.5 $46,499 - $61,835
24,734 Added 53.92%
70,605 $148,000
Q2 2022

Aug 12, 2022

BUY
$2.63 - $5.61 $3,852 - $8,218
1,465 Added 3.3%
45,871 $130,000
Q4 2021

Feb 08, 2022

BUY
$7.29 - $9.5 $143,853 - $187,463
19,733 Added 79.98%
44,406 $332,000
Q3 2021

Nov 15, 2021

SELL
$4.22 - $12.48 $6,043 - $17,871
-1,432 Reduced 5.49%
24,673 $224,000
Q2 2021

Aug 13, 2021

BUY
$3.62 - $4.88 $14,740 - $19,871
4,072 Added 18.48%
26,105 $127,000
Q1 2021

May 12, 2021

BUY
$3.53 - $8.06 $307 - $701
87 Added 0.4%
22,033 $98,000
Q4 2020

Feb 11, 2021

BUY
$3.07 - $4.66 $3,954 - $6,002
1,288 Added 6.23%
21,946 $85,000
Q2 2020

Aug 14, 2020

BUY
$2.55 - $4.58 $52,677 - $94,613
20,658 New
20,658 $92,000

Others Institutions Holding LIFE

About aTYR PHARMA INC


  • Ticker LIFE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 28,625,000
  • Market Cap $53.2M
  • Description
  • aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for ...
More about LIFE
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.